Aprogen Biologics Inc. (KRX:003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,738.00
-62.00 (-3.44%)
Sep 1, 2026, 3:30 PM KST

Aprogen Biologics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-78,296-170,331-104,979-118,27012,6398,103
Depreciation & Amortization
19,41119,18519,09021,3982,4042,072
Loss (Gain) From Sale of Assets
-17.16-88.69-16.15151,537-3.1-53.08
Asset Writedown & Restructuring Costs
637.76637.76154.082,271264.152,134
Loss (Gain) From Sale of Investments
1,7679,6169,934-34,724-1,380-1,623
Loss (Gain) on Equity Investments
7,48677,37729,047-75,012-1,353-352.2
Provision & Write-off of Bad Debts
-10,086-0.490.01-24.29-2,224-26.23
Other Operating Activities
34,40328,25016,98031,1641,476-720.21
Change in Accounts Receivable
4,9873,021-2,2171,218-637.92-494.75
Change in Inventory
-4,562-149.22-5,708-3,284-1,180-1,023
Change in Accounts Payable
-401.92-613.74662.83-2,373313.46-155.63
Change in Other Net Operating Assets
-7,650-5,1366,056-7,55015,410-14,088
Operating Cash Flow
-32,320-38,233-30,996-33,65125,728-6,227
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,817-9,625-15,264-28,088-1,284-796.19
Sale of Property, Plant & Equipment
168.45210.716.5316.8216.3666.71
Cash Acquisitions
32,500-5,080--9,223--
Divestitures
2,6222,622200-3,074-
Sale (Purchase) of Intangibles
1,003-154.86-187.34-308.06-261.4-145.94
Investment in Securities
-27,418-880.82-12,262-79,69022,19775,048
Other Investing Activities
-55,130-72,212-24,22522,086-76,742-97,329
Investing Cash Flow
-50,070-85,119-51,722-95,206-53,001-23,156

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-41,80053,95049,61020,500-
Long-Term Debt Issued
-97,97239,997114,611--
Total Debt Issued
88,374139,77293,947164,22120,500-
Short-Term Debt Repaid
--3,000-60,650-122,110-4,000-
Long-Term Debt Repaid
--1,635-61,594-353.06-262.55-349.3
Total Debt Repaid
-11,793-4,635-122,244-122,463-4,263-349.3
Net Debt Issued (Repaid)
76,581135,136-28,29741,75816,237-349.3
Issuance of Common Stock
1,9960.61115,75940,0000.24-
Repurchase of Common Stock
-72.78--21.72-4,425--
Other Financing Activities
-13-0.08-2,46837,957-455.34-0.96
Financing Cash Flow
78,491135,13784,972115,28915,782-350.26

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
595.4301.4-11.6525.0411.02
Miscellaneous Cash Flow Adjustments
----0-0
Net Cash Flow
-3,30512,0862,253-13,555-11,465-29,722

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-36,137-47,857-46,261-61,73924,444-7,023
Free Cash Flow Growth
------
Free Cash Flow Margin
-41.93%-65.36%-68.66%-70.67%37.50%-12.43%
Free Cash Flow Per Share
-2701.64-3633.40-5516.48-14680.219071.14-2642.97
Levered Free Cash Flow
-69,079-82,778-24,02613,979104,474-97,245
Unlevered Free Cash Flow
-59,834-76,091-20,57916,272104,645-97,226

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
8,5584,9302,213151.0425.7789.51
Cash Income Tax Paid
465.781,736-31.26-2,4852,1151,810
Change in Working Capital
-7,627-2,878-1,207-11,99013,906-15,761